Current and emerging direct-acting antivirals (DAAs) promise to impact greatly in the management of hepatitis C both prior to and after transplantation. Patients with cirrhosis, patients on waiting lists for liver transplantation, and liver recipients represent populations with the greatest need for effective new therapies. Certainly investigators have the possibility to submit their research in this area to major international conferences, but there is usually limited time for in-depth discussion and debate among experts on new data and their implications.
In 2013, we established a workshop, “The First International Workshop on DAAs in Liver Transplantation”. This Workshop and our assembled group of experts focused on the unmet need for a state of the art, scientific and independent platform for international exchange between experts in the field of liver transplantation. The success of this first workshop in Amsterdam on 23 April 2013 and the second workshop on 8 April 2014 in London confirmed the need for this initiative.
It is therefore our pleasure to announce the 3rd International Workshop on the Optimal Use of DAAs in Advanced Liver Disease and Transplantation, to be held in Vienna, Austria on 21 April 2015 preceding the EASL.
The format will be a one-day program with invited lectures, panel discussions and case presentations. We will emphasize the nature of the meeting and allocate much of meeting time for Q&A sessions and roundtable discussions. The workshop will assemble researchers and clinicians in order to allow presentation and discussion of the latest developments in an open environment.
We hope you will be able to join us this year and we look forward to seeing you in Vienna.
Yours sincerely, On behalf of the Organizing Committee
Greg T. Everson (Chair 2015)